This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
This month’s cover molecule, BMS-986278, is an LPA1 antagonist and oral (up to 125 mg BID) Ph. II clinical candidate for idiopathic…
molecule
1 year ago ●
2 mins read
The bifunctional degrader, SJ995973, was nominated by Joachim Rudolph. “Instead of the thalidomide-based cereblon binder present in the established BET degrader tool…
molecule
1 year ago ●
1 min read
The Carna Biosciences CDC7 kinase inhibitor, AS-0141, is a clinical candidate for cancer with a structure that contains a hydrazine, furenone,…
molecule
1 year ago ●
1 min read
The Cytokinetics next-generation myosin inhibitor, aficamten, is a phase II candidate for genetic hypertrophic cardiomyopathies, and is orally dosed between 5-30…
molecule
1 year ago ●
1 min read
The Pfizer CFTR potentiator, CP-628006, enhances CFTR function in cystic fibrosis patient-derived airwell cells with a distinct mechanism of action from…
molecule
1 year ago ●
1 min read
The Cytokinetics second generation troponin activator, reldesemtiv, is intended to treat muscle weakness by directly activating skeletal muscle. A high concentration…
molecule
1 year ago ●
2 mins read
Load More
